The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors

Open Medicinal Chemistry Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 3-9

  Smith, Sean M ^a   Uslaner, Jason M ^a   Hutson, Peter H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

D serine. D amino acid oxidase; NMDA receptor; Schizophrenia

Indexed keywords

3 HYDROXYQUINOLIN 2(1H) ONE; 5 METHYL 3 PYRAZOLECARBOXYLIC ACID; ASO 57278; ATYPICAL ANTIPSYCHOTIC AGENT; BENZOIC ACID; CBIO; DEXTRO ALANINE; DEXTRO AMINO ACID OXIDASE; DEXTRO SERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; BEHAVIOR; CATALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; NEPHROTOXICITY; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA;

EID: 78249248949     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501004020003     Document Type: Article

References (55)

1. Krebs, H. A. Metabolism of amino-acids: deamination of amino-acids. Biochem. J., 1935, 29, 1620-1644.
2. Konno, R. Assignment of D-amino-acid oxidase gene to a human and a mouse chromosome. Amino Acids, 2001, 20, 401-408.
3. Tishkov, V. I.; Khoronenkova, S. V. D-Amino acid oxidase: structure, catalytic mechanism, and practical application. Biochemistry (Mosc), 2005, 70, 40-54.
4. Pilone, M. S. D-Amino acid oxidase: new findings. Cell Mol. Life Sci., 2000, 57, 1732-1747.
5. Piubelli, L.; Caldinelli, L.; Molla, G.; Pilone, M. S.; Pollegioni, L. Conversion of the dimeric D-amino acid oxidase from Rhodotorula gracilis to a monomeric form. A rational mutagenesis approach. FEBS Lett., 2002, 526, 43-48.
6. Hasegawa, H.; Matsukawa, T.; Shinohara, Y.; Konno, R.; Hashimoto, T. Role of renal D-amino-acid oxidase in pharmacokinetics of D-leucine. Am. J. Physiol. Endocrinol. Metab., 2004, 287, E160-E165.
7. Momoi, K.; Fukui, K.; Watanabe, F.; Miyake, Y. Molecular cloning and sequence analysis of cDNA encoding human kidney D-amino acid oxidase. FEBS Lett., 1988, 238, 180-184.
8. Katagiri, M.; Tojo, H.; Horiike, K.; Yamano, T. Immunochemical relationship of D-amino acid oxidases in various tissues and animals. Comp. Biochem. Physiol. B, 1991, 99, 345-350.
9. Horiike, K.; Tojo, H.; Arai, R.; Nozaki, M.; Maeda, T. D-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes. Brain Res., 1994, 652, 297-303.
10. Verrall, L.; Walker, M.; Rawlings, N.; Benzel, I.; Kew, J. N.; Harrison, P. J.; Burnet, P. W. d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur. J. Neurosci., 2007, 26, 1657-1669.
11. Wang, Q.; Cwik, M.; Wright, C. J.; Cunningham, F.; Pelligrino, D. A. The in vivo unidirectional conversion of nitro-D-arginine to nitro-L-arginine. J. Pharmacol. Exp. Ther., 1999, 288, 270-273.
12. Takigawa, Y.; Homma, H.; Lee, J. A.; Fukushima, T.; Santa, T.; Iwatsubo, T.; Imai, K. D-aspartate uptake into cultured rat pinealocytes and the concomitant effect on L-aspartate levels and melatonin secretion. Biochem. Biophys. Res. Commun., 1998, 248, 641-647.
13. D'Aniello, G.; Tolino, A.; D'Aniello, A.; Errico, F.; Fisher, G. H.; Di Fiore, M. M. The role of D-aspartic acid and N-methyl-D-aspartic acid in the regulation of prolactin release. Endocrinology, 2000, 141, 3862-70.
14. Fisher, G.; Lorenzo, N.; Abe, H.; Fujita, E.; Frey, W. H.; Emory, C.; Di Fiore, M. M.; A, D. A. Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. Amino Acids, 1998, 15, 263-269.
15. Johnson, J. W.; Ascher, P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature, 1987, 325, 529-531.
16. Kemp, J. A.; Leeson, P. D. The glycine site of the NMDA receptor- -five years on. Trends Pharmacol. Sci., 1993, 14, 20-25.
17. Mothet, J. P.; Parent, A. T.; Wolosker, H.; Brady, R. O., Jr.; Linden, D. J.; Ferris, C. D.; Rogawski, M. A.; Snyder, S. H. D-serine is an endogenous ligand for the glycine site of the N-methyl- D-aspartate receptor. Proc. Natl. Acad. Sci. USA, 2000, 97, 4926-4931.
18. Ito, K.; Hicks, T. P. Effect of the glycine modulatory site of the N- methyl-D-aspartate receptor on synaptic responses in kitten visual cortex. Neurosci. Lett., 2001, 303, 95-98.
19. Shleper, M.; Kartvelishvily, E.; Wolosker, H. D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. J. Neurosci., 2005, 25, 9413-9417.
20. Lieberman, J. A.; Bymaster, F. P.; Meltzer, H. Y.; Deutch, A. Y.; Duncan, G. E.; Marx, C. E.; Aprille, J. R.; Dwyer, D. S.; Li, X. M.; Mahadik, S. P.; Duman, R. S.; Porter, J. H.; Modica-Napolitano, J. S.; Newton, S.S.; Csernansky, J.G. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol. Rev., 2008, 60, 358-403.
21. Uslaner, J.; Surles, N.; Vardigan, J.; Huszar, S.; Hutson, P. The mGluR5 positive allosteric modulator, CDPPB, has antipsychotic effects, improves memory, and increases hedonia: relevance to schizophrenia: International Congress on Schizophrenia Research, San Diego, CA, USA, 2009.
22. Javitt, D. C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry, 1987, 9, 12-35.
23. Krystal, J. H.; Karper, L. P.; Seibyl, J. P.; Freeman, G. K.; Delaney, R.; Bremner, J. D.; Heninger, G. R.; Bowers, M. B., Jr.; Charney, D. S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry, 1994, 51, 199-214.
24. Lahti, A. C.; Warfel, D.; Michaelidis, T.; Weiler, M. A.; Frey, K.; Tamminga, C. A. Long-term outcome of patients who receive ketamine during research. Biol. Psychiatry, 2001, 49, 869-875.
25. Hashimoto, K.; Fukushima, T.; Shimizu, E.; Komatsu, N.; Watanabe, H.; Shinoda, N.; Nakazato, M.; Kumakiri, C.; Okada, S.; Hasegawa, H.; Imai, K.; Iyo, M. Decreased serum levels of D- serine in patients with schizophrenia: evidence in support of the N- methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry, 2003, 60, 572-576.
26. Hashimoto, K.; Engberg, G.; Shimizu, E.; Nordin, C.; Lindstrom, L. H.; Iyo, M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29, 767-769.
27. Bendikov, I.; Nadri, C.; Amar, S.; Panizzutti, R.; De Miranda, J.; Wolosker, H.; Agam, G. A CSF and postmortem brain study of D- serine metabolic parameters in schizophrenia. Schizophr. Res., 2007, 90, 41-51.
28. Yamada, K.; Ohnishi, T.; Hashimoto, K.; Ohba, H.; Iwayama- Shigeno, Y.; Toyoshima, M.; Okuno, A.; Takao, H.; Toyota, T.; Minabe, Y.; Nakamura, K.; Shimizu, E.; Itokawa, M.; Mori, N.; Iyo, M.; Yoshikawa, T. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol. Psychiatry, 2005, 57, 1493-1503.
29. Heresco-Levy, U.; Javitt, D. C.; Ermilov, M.; Mordel, C.; Horowitz, A.; Kelly, D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry, 1996, 169, 610-617.
30. Heresco-Levy, U.; Javitt, D. C.; Ermilov, M.; Mordel, C.; Silipo, G.; Lichtenstein, M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry, 1999, 56, 29-36.
31. Heresco-Levy, U.; Ermilov, M.; Shimoni, J.; Shapira, B.; Silipo, G.; Javitt, D. C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry, 2002, 159, 480-482.
32. Tsai, G.; Yang, P.; Chung, L. C.; Lange, N.; Coyle, J. T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry, 1998, 44, 1081-1089.
33. Chumakov, I.; Blumenfeld, M.; Guerassimenko, O.; Cavarec, L.; Palicio, M.; Abderrahim, H.; Bougueleret, L.; Barry, C.; Tanaka, H.; La Rosa, P.; Puech, A.; Tahri, N.; Cohen-Akenine, A.; Delabrosse, S.; Lissarrague, S.; Picard, F. P.; Maurice, K.; Essioux, L.; Millasseau, P.; Grel, P.; Debailleul, V.; Simon, A. M.; Caterina, D.; Dufaure, I.; Malekzadeh, K.; Belova, M.; Luan, J. J.; Bouillot, M.; Sambucy, J. L.; Primas, G.; Saumier, M.; Boubkiri, N.; Martin- Saumier, S.; Nasroune, M.; Peixoto, H.; Delaye, A.; Pinchot, V.; Bastucci, M.; Guillou, S.; Chevillon, M.; Sainz-Fuertes, R.; Meguenni, S.; Aurich-Costa, J.; Cherif, D.; Gimalac, A.; Van Duijn, C.; Gauvreau, D.; Ouellette, G.; Fortier, I.; Raelson, J.; Sherbatich, T.; Riazanskaia, N.; Rogaev, E.; Raeymaekers, P.; Aerssens, J.; Konings, F.; Luyten, W.; Macciardi, F.; Sham, P. C.; Straub, R. E.; Weinberger, D. R.; Cohen, N.; Cohen, D. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad Sci., USA, 2002, 99, 13675-13680.
34. Burnet, P. W.; Eastwood, S. L.; Bristow, G. C.; Godlewska, B. R.; Sikka, P.; Walker, M.; Harrison, P. J. D-amino acid oxidase activity and expression are increased in schizophrenia. Mol. Psychiatry, 2008, 13, 658-660.
35. Hashimoto, A.; Nishikawa, T.; Konno, R.; Niwa, A.; Yasumura, Y.; Oka, T.; Takahashi, K. Free D-serine, D-aspartate and D- alanine in central nervous system and serum in mutant mice lacking D-amino acid oxidase. Neurosci. Lett., 1993, 152, 33-36.
36. Maekawa, M.; Watanabe, M.; Yamaguchi, S.; Konno, R.; Hori, Y. Spatial learning and long-term potentiation of mutant mice lacking D-amino-acid oxidase. Neurosci. Res., 2005, 53, 34-38.
37. Wake, K.; Yamazaki, H.; Hanzawa, S.; Konno, R.; Sakio, H.; Niwa, A.; Hori, Y. Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-D-aspartate receptor- mediated synaptic transmission in mutant mice lacking D-amino- acid oxidase. Neurosci. Lett., 2001, 297, 25-28.
38. Almond, S. L.; Fradley, R. L.; Armstrong, E. J.; Heavens, R. B.; Rutter, A. R.; Newman, R. J.; Chiu, C. S.; Konno, R.; Hutson, P. H.; Brandon, N. J. Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia. Mol. Cell Neurosci., 2006, 32, 324-334.
39. Adage, T.; Trillat, A. C.; Quattropani, A.; Perrin, D.; Cavarec, L.; Shaw, J.; Guerassimenko, O.; Giachetti, C.; Greco, B.; Chumakov, I.; Halazy, S.; Roach, A.; Zaratin, P. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur. Neuropsychopharmacol., 2008, 18, 200-214.
40. Duplantier, A. J.; Becker, S. L.; Bohanon, M. J.; Borzilleri, K. A.; Chrunyk, B. A.; Downs, J. T.; Hu, L. Y.; El-Kattan, A.; James, L. C.; Liu, S.; Lu, J.; Maklad, N.; Mansour, M. N.; Mente, S.; Piotrowski, M. A.; Sakya, S. M.; Sheehan, S.; Steyn, S. J.; Strick, C. A.; Williams, V. A.; Zhang, L. Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors. J. Med. Chem., 2009, 52, 3576-3585.
41. Sparey, T.; Abeywickrema, P.; Almond, S.; Brandon, N.; Byrne, N.; Campbell, A.; Hutson, P. H.; Jacobson, M.; Jones, B.; Munshi, S.; Pascarella, D.; Pike, A.; Prasad, G. S.; Sachs, N.; Sakatis, M.; Sardana, V.; Venkatraman, S.; Young, M. B. The discovery of fused pyrrole carboxylic acids as novel, potent D-amino acid oxidase (DAO) inhibitors. Bioorg.Med. Chem. Lett., 2008, 18, 3386-3391.
42. Smith, S. M.; Uslaner, J. M.; Yao, L.; Mullins, C. M.; Surles, N. O.; Huszar, S. L.; McNaughton, C. H.; Pascarella, D. M.; Kandebo, M.; Hinchliffe, R. M.; Sparey, T.; Brandon, N. J.; Jones, B.; Venkatraman, S.; Young, M. B.; Sachs, N.; Jacobson, M. A.; Hutson, P. H. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2- b]pyrrole-5-carboxylic acid] and D-serine. J. Pharmacol. Exp. Ther., 2009, 328, 921-930.
43. Ferraris, D.; Duvall, B.; Ko, Y. S.; Thomas, A. G.; Rojas, C.; Majer, P.; Hashimoto, K.; Tsukamoto, T. Synthesis and biological evaluation of D-amino acid oxidase inhibitors. J. Med. Chem., 2008, 51, 3357-3359.
44. Hashimoto, K.; Fujita, Y.; Horio, M.; Kunitachi, S.; Iyo, M.; Ferraris, D.; Tsukamoto, T. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol. Psychiatry, 2009, 65, 1103-1106.
45. Contreras, P. C. D-serine antagonized phencyclidine- and MK-801- induced stereotyped behavior and ataxia. Neuropharmacology, 1990, 29, 291-293.
46. Lipina, T.; Labrie, V.; Weiner, I.; Roder, J. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl), 2005, 179, 54-67.
47. Hashimoto, K.; Fujita, Y.; Ishima, T.; Chaki, S.; Iyo, M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. Eur. Neuropsychopharmacol., 2008, 18, 414-421.
48. Karasawa, J.; Hashimoto, K.; Chaki, S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav. Brain Res., 2008, 186, 78-83.
49. Krug, A. W.; Volker, K.; Dantzler, W. H.; Silbernagl, S. Why is D- serine nephrotoxic and alpha-aminoisobutyric acid protective? Am. J. Physiol. Renal. Physiol., 2007, 293, F382-F390.
50. Yoshikawa, M.; Ito, K.; Maeda, M.; Akahori, K.; Takahashi, S.; Jin, X. L.; Matsuda, M.; Suzuki, T.; Oka, T.; Kobayashi, H.; Hashimoto, A. Activation of supraspinal NMDA receptors by both D-serine alone or in combination with morphine leads to the potentiation of antinociception in tail-flick test of rats. Eur. J. Pharmacol., 2007, 565, 89-97.
51. Ito, K.; Yoshikawa, M.; Maeda, M.; Jin, X. L.; Takahashi, S.; Matsuda, M.; Tamaki, R.; Kobayashi, H.; Suzuki, T.; Hashimoto, A. Midazolam attenuates the antinociception induced by d-serine or morphine at the supraspinal level in rats. Eur. J. Pharmacol., 2008, 586, 139-144.
52. Kolhekar, R.; Meller, S. T.; Gebhart, G. F. N-methyl-D-aspartate receptor-mediated changes in thermal nociception: allosteric modulation at glycine and polyamine recognition sites. Neuroscience, 1994, 63, 925-936.
53. Parsons, C. G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol., 2001, 429, 71-78.
54. Ren, W. H.; Guo, J. D.; Cao, H.; Wang, H.; Wang, P. F.; Sha, H.; Ji, R. R.; Zhao, Z. Q.; Zhang, Y. Q. Is endogenous D-serine in the rostral anterior cingulate cortex necessary for pain-related negative affect? J. Neurochem., 2006, 96, 1636-1647.
55. Zhao, W.; Konno, R.; Zhou, X. J.; Yin, M.; Wang, Y. X. Inhibition of D-amino-Acid oxidase activity induces pain relief in mice. Cell Mol. Neurobiol., 2008, 28, 581-591.